A study testing whether a GLP-1 medicine from Yale University, semaglutide, can lower blood sugar and help with weight.
- Who can join
- Adults 18 to 30, have type 1 diabetes, BMI 27+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 3.9 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Diabetes type1. Also studied in: Obesity.
Full scientific study title: Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment.
Who can join
Adults 18 to 30, have type 1 diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI >=30 kg/m2 alone or BMI >=27 kg/m2 with a weight-related comorbidity)
- Clinical diagnosis of T1D
- Diabetes duration diagnosed >= 12 months ago
- HbA1c <=10% at screening and within the past 90 days
- Stable reported insulin dosing in the past 90 days (within 15%)
Key exclusion criteria
- Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months.
- Insulin dosing <0.5 units/kg/day
- Current psychiatric conditions impacting weight, including known eating disorders
- Contraindications to study medications, including:
- Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Connecticut1 site
- Yale Pediatric Diabetes Center, Adult and Children's ProgamNew Haven, Connecticut
Timeline
Started enrolling: 2024-07-16. Expected completion: 2028-06-30. Last updated on ClinicalTrials.gov: 2025-05-02.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
